What is CardioFocus?
CardioFocus is at the forefront of developing advanced electrophysiology tools designed for the treatment of atrial fibrillation, with a particular emphasis on pulsed field ablation technology. Their product suite includes sophisticated catheters and generators engineered for precise and efficient cardiac ablation procedures. The company's mission is to equip electrophysiologists with integrated therapy platforms that enhance treatment outcomes, thereby improving patient care and streamlining clinical workflows. CardioFocus targets healthcare professionals within the electrophysiology sector, offering solutions that aim to optimize both procedural efficacy and patient well-being.
How much funding has CardioFocus raised?
CardioFocus has raised a total of $235.3M across 16 funding rounds:
Multiple Rounds
$49.2M
Multiple Rounds
$36.3M
Private Equity
$8M
Private Equity
$20.2M
Debt
$21M
Unspecified
$55M
Debt
$1M
Private Equity (2011): $13.6M, investors not publicly disclosed
Unspecified (2011): $30.6M led by The Aurora Funds, Inc., KBL Healthcare Ventures, Manatuck Hill Partners, First Alliance & Capital Invest, SV Life Sciences, H.I.G. Capital, Accuitive Medical Ventures, Oxford Bioscience Partners, and Fletcher Spaght Ventures
Debt (2011): $5M supported by Silicon Valley Bank
Debt (2014): $2.4M featuring The Aurora Funds, SV Life Sciences, Fletcher Spaght Ventures, LP, H.I.G. Capital, Accuitive Medical Ventures, and Oxford Bioscience Partners
Debt (2014): $2.3M backed by KBL Healthcare Ventures, Aurora Funds, Accuitive Medical Ventures, Allied Minds, and S.V. Life Sciences
Private Equity (2014): $31.7M with participation from KBL Healthcare Ventures, Aurora Funds, Accuitive Medical Ventures, H.I.G.. BioVentures, Allied Minds, and S.V. Life Sciences
Private Equity (2016): $8M led by Allied Minds, S.V. Life Sciences, KBL Healthcare Ventures, Aurora Funds, Accuitive Medical Ventures, and H.I.G. BioVentures
Private Equity (2017): $20.2M, investors not publicly disclosed
Debt (2018): $21M featuring GPB Capital
Unspecified (2019): $55M backed by Kennedy Lewis Investment Management
Debt (2020): $1M with participation from PPP
Key Investors in CardioFocus
The Aurora Funds, Inc.
The Aurora Funds is a venture capital firm that provides capital, connections and strategic guidance to entrepreneurs with early-stage healthcare and information technology companies. Founded in 1994, Aurora manages over $234 million in five venture funds. The firm's three investment professionals have over 45 years of combined venture capital investing and operational experience.
S.V. Life Sciences
SV Health Investors is a specialist investment firm backing innovative health care and life science companies, partnering with founders and management to provide capital, sector expertise and active support from early growth through scale and value creation.
KBL Healthcare Ventures
KBL Healthcare Ventures is focused on investing in innovative healthcare companies that are addressing unmet medical needs. Their portfolio includes a range of products and services aimed at improving patient care and outcomes. The intended clients are early-stage healthcare companies looking for financial support and strategic guidance. Through their investment strategies, KBL aims to drive advancements in the healthcare sector.
What's next for CardioFocus?
The substantial capital infusion positions CardioFocus for accelerated growth and innovation. With a focus on pulsed field ablation, the company is poised to expand its market reach and further develop its technology. Future strategic initiatives will likely involve scaling manufacturing, enhancing research and development for next-generation devices, and broadening clinical adoption. The company's trajectory suggests a strong commitment to addressing unmet needs in cardiac electrophysiology, potentially leading to significant advancements in patient treatment and care.
See full CardioFocus company page
